drugset
drugset / Trial / NCT00335660

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

NCT00335660 ↗

Phase 2 Terminated 62 enrolled Avera Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.

Timeline

Start
2006-06
Primary completion
2007-06
Completion
2007-09

Outcome

Outcome not reported

Stopped: “Animal Safety Data”

Drugs

EvaluationDrugModalityDoseRoute
Subject AV608 Unknown — —

Indications

overactive bladder